cb-13 cb-13 cb-13 (cra13, sab-378) is a cannabinoid drug, which acts as a potent agonist at both the cb1 and cb2 receptors, but has poor blood–brain barrier penetration, and so produces only peripheral effects at low doses, with symptoms of central effects such as catalepsy only appearing at much higher dose ranges. it has antihyperalgesic properties in animal studies, and has progressed to preliminary human trials. cb-13legal statuslegal status ca: schedule ii identifiers iupac name naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone cas number432047-72-8 ypubchem cid9799417chemspider7975182unii9xrj6055xtchemblchembl244403comptox dashboard (epa)dtxsid60430920 chemical and physical dataformulac26h24o2molar mass368.476 g·mol−13d model (jsmol)interactive image smiles c13ccccc1cccc3c(=o)c4ccc(occccc)c2ccccc24 inchi inchi=1s/c26h24o2/c1-2-3-8-18-28-25-17-16-24(21-13-6-7-14-22(21)25)26(27)23-15-9-11-19-10-4-5-12-20(19)23/h4-7,9-17h,2-3,8,18h2,1h3key:rsumdjrtafbisx-uhfffaoysa-n (verify) legal status as of october 2015 cb-13 is a controlled substance in china.